Document is current
Any future updates will be listed below
-
Authors
Hu, Xingsheng
Zhang, Shucai
Ma, Zhiyong
Feng, Jifeng
Wu, Lin
Lv, Dongqing
Zhou, Jianying
Zhang, Xiaodong
Liu, Li
Yu, Qitao
Liao, Wangjun
Zhang, Yiping
Wang, Xiang
Cheng, Ying
Niu, Hongrui
Wang, Ziping
Wang, Dong
Huang, Cheng
Liu, Chunling
Zhao, Hui
Feng, Jian
Li, Jingzhang
Ying, Kejing
Yang, Nong
Qin, Shukui
Hu, Jie
Liu, Fei
Jiang, Yong
Ge, Nan
Shi, Yuankai https://orcid.org/0000-0002-3342-4964
-
Funding
Funding for this research was provided by:
China National Major Project for New Drug Innovation
- License Information
-
More Information
Article History
Received: 21 December 2022
Accepted: 14 April 2023
First Online: 28 April 2023
Declarations
:
: Both studies were conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. Studies were approved by the institutional review board of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (approval number of phase 2a study of furmonertinib: 17–057/1312, approval number of phase 2a study of furmonertinib: 18–008/1472), along with all participating institutions. Written informed consent forms were obtained from each patient before enrolment.
: Not applicable.
: JH, FL, YJ and NG are employees and shareholders of Shanghai Allist Pharmaceuticals Co., Ltd, Shanghai, China. No other competing interests were reported.
